The original success of the copyright undeniably revolutionized the medication landscape, but placing funds in companies primarily reliant on generic versions presents a uncertain picture. While early returns were substantial, the expiration of patents and the rise of less expensive alternatives have diminished the customer base. Thus, a thorough a